ATEZO	Atezolizumab
BMI	body mass index
CR	complete response
CTLA-4	cytotoxic T lymphocyte antigen-4
ICI	immune-checkpoint inhibitor
IL-2	interleukin-2
IQR	interquartile range
NIVO	nivolumab
NSCLC	non-small-cell lung carcinoma
OR	objective response
ORR	objective response rate
OS	overall survival
PD	progressive disease
PD-1	programmed cell death protein 1
PD-L1	programmed cell death ligand 1
PEMBRO	pembrolizumab
PFS	progression-free survival
PR	partial response
RECIST	Response Evaluation Criteria in Solid Tumors
sCD25	soluble form of the unit α of interleukin-2 receptor (sIL-2Rα)
sd	standard deviation
SD	stable disease
Tregs	regulatory T cells
TTF	time to treatment failure